Daniels, Stephen <br/><br/>
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.  [electronic resource] 

 -  Journal of clinical lipidology   
 - 322-330.e5 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1933-2874 
<br/><br/><label>Standard No.: </label>10.1016/j.jacl.2020.03.001  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Anticholesteremic Agents--therapeutic use<br/>Child<br/>Double-Blind Method<br/>Female<br/>Heterozygote<br/>Humans<br/>Hyperlipoproteinemia Type II--drug therapy<br/>Male<br/>Middle Aged<br/>PCSK9 Inhibitors<br/>Treatment Outcome